1. Home
  2. PLCE vs ONCY Comparison

PLCE vs ONCY Comparison

Compare PLCE & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Children's Place Inc. (The)

PLCE

Children's Place Inc. (The)

HOLD

Current Price

$2.84

Market Cap

92.8M

ML Signal

HOLD

Logo Oncolytics Biotech Inc.

ONCY

Oncolytics Biotech Inc.

HOLD

Current Price

$0.95

Market Cap

98.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLCE
ONCY
Founded
1969
1998
Country
United States
Canada
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Pharmaceuticals and Biotechnology
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
92.8M
98.7M
IPO Year
1997
2002

Fundamental Metrics

Financial Performance
Metric
PLCE
ONCY
Price
$2.84
$0.95
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$3.50
$7.33
AVG Volume (30 Days)
448.1K
1.6M
Earning Date
04-10-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
11.48
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.41
$2,505.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.76
$0.71
52 Week High
$9.56
$1.51

Technical Indicators

Market Signals
Indicator
PLCE
ONCY
Relative Strength Index (RSI) 34.33 56.82
Support Level N/A $0.90
Resistance Level $3.81 $1.06
Average True Range (ATR) 0.26 0.06
MACD -0.09 0.01
Stochastic Oscillator 2.59 75.14

Price Performance

Historical Comparison
PLCE
ONCY

About PLCE Children's Place Inc. (The)

Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It designs, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names. The Company classifies its business into two segments: The Children's Place U.S. and The Children's Place International.

About ONCY Oncolytics Biotech Inc.

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.

Share on Social Networks: